News >

Choueiri Highlights Promising Avelumab/Axitinib Data in RCC

Brandon Scalea
Published: Tuesday, Nov 20, 2018

Toni K. Choueiri, MD

Toni K. Choueiri, MD
The combination of axitinib (Inlyta) and avelumab (Bavencio) demonstrated a significant improvement in objective response rates (ORR) and progression-free survival (PFS) compared with single-agent sunitinib (Sutent) in previously untreated patients with metastatic renal cell carcinoma (RCC), according to pivotal phase III findings.

The biggest challenge associated with the JAVELIN Renal 101 trial, said senior author Toni K. Choueiri, MD, is deciding when to use this combination.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication